Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PKLR | P30613 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711461 | 0.84 | PIK3CA (0.34) | PKMNPSR1RXFP1PIK3CASMN1; SMN2 | |
| SCHEMBL14850021 | 0.81 | PIK3CA (0.33) | PIK3CASMN1; SMN2PDE7A | |
| SCHEMBL16441111 | 0.81 | SMN1; SMN2 (0.37) | PIK3CASMN1; SMN2PDE7AADORA2BRAB9A | |
| SCHEMBL19492381 | 0.78 | ADORA2B (0.35) | PIK3CAPDE7AADORA2B | |
| SCHEMBL18711470 | 0.78 | ADORA2B (0.33) | PIK3CAADORA2B | |
| SCHEMBL18701516 | 0.78 | ADORA2A (0.32) | PIK3CA | |
| SCHEMBL30259996 | 0.76 | — | — | |
| SCHEMBL5850870 | 0.76 | PDE4B (0.36) | PIK3CAPDE7AADORA2BRAB9A | |
| SCHEMBL14975382 | 0.73 | PIK3CA (0.44) | PIK3CA | |
| SCHEMBL20665233 | 0.70 | KDM4E (0.46) | NPSR1ADORA2BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044068-B2 | Aminopyrrolidine compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-2003131-A1 | AMINOPYRROLIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007023382-A2 | PYRIMIDINE AMINO PYRAZOLE COMPOUNDS, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1544202-A1 | NOVEL HERBICIDES, USAGE THEREOF, NOVEL THIENOPYRIMIDINE DERIVATIVES, INTERMEDIATES OF THE SAME, AND PROCESS FOR PRODUCTION THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | PKM 4685/4885NPSR1 2574/4885RXFP1 1137/4885 |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | DDT, DPYD, DHODH | PKM 1773/4885NPSR1 4056/4885RXFP1 4681/4885 |
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | MC4R, MC5R, MC2R | PKM 782/4885NPSR1 159/4885RXFP1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.